Imugene secures $2.7 million R&D tax refund to advance cancer pipeline
Imugene Limited (ASX: IMU) has received its R&D tax refund for the 2025 financial year, totalling A$2,738,618 (including A$10,911 interest). The non-dilutive funding arrives following the company’s recent FDA meeting and positive clinical results, providing capital to support continued clinical development without shareholder dilution.
The refund was received under the Australian Government’s R&D Tax Incentive programme, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 48.5%. For pre-revenue biotechnology companies like Imugene, this represents predictable annual support that extends cash runway without requiring capital raises.
How the R&D Tax Incentive supports Australian biotechs
The Australian R&D Tax Incentive is a government programme designed to encourage innovation by providing financial support for research and development activities. Companies conducting eligible R&D can receive a refundable tax offset, meaning they receive cash back rather than just a tax credit.
For clinical-stage biotechnology companies that generate no revenue while conducting trials, this refundable offset provides crucial non-dilutive funding. Investors can factor these recurring annual refunds into cash runway calculations, as they represent predictable support each financial year for companies maintaining eligible R&D programmes.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Funds to support Imugene’s immuno-oncology pipeline
The A$2.74 million refund will enable further clinical development of Imugene’s immuno-oncology assets. The company’s platform includes:
- Azer-cel (azercabtagene zapreleucel) — an off-the-shelf (allogeneic) CAR T therapy targeting CD19 for blood cancers
- onCARlytics — oncolytic virotherapy aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours
The funding comes at what management described as “a pivotal time” following the company’s recent FDA meeting and positive clinical results, providing incremental capital to advance programmes that have recently generated regulatory and clinical catalysts.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What this means for Imugene shareholders
The FY25 R&D tax refund represents a modest but meaningful capital injection that requires no shareholder dilution. While the $2.74 million amount is relatively small against total R&D expenditure for a clinical-stage biotech, it provides predictable annual support that reduces reliance on equity raises or debt financing.
Shareholders can expect similar refunds in future financial years as long as Imugene maintains eligible R&D activities. The funds support continued progress towards key clinical and regulatory milestones across the company’s immuno-oncology pipeline, with recent momentum from FDA engagement and clinical data positioning the programmes for further development.
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements drop across Healthcare, Tech, Finance and more.